A Case of Sertoli-Leydig Cell Tumor with Raised Alpha-Fetoprotein In a Patient with Thyroid Adenoma.

Oh, Jong Yn; Kang, Kwang Sok; Park, Seon Young; Moon, Jeong Beom; Kim, Kyoung A; Lee, Young Ho; Lee, Keum Nho

Case Report

Korean Journal of Obstetrics & Gynecology 2004;47(6):1255-1260.
Published online June 1, 2004.

A Case of Sertoli-Leydig Cell Tumor with Raised Alpha-Fetoprotein In a Patient with Thyroid Adenoma.

Jong Yn Oh, Kwang Sok Kang, Seon Young Park, Jeong Beom Moon, Kyoung A Kim, Young Ho Lee, Keum Nho Lee

¹Department of Obstetrics and Gynecology, Presbyterian Medical Center, Chon-Ju, Korea.
²Mi-Rae Women's Clinic, Chon-Ju, Korea.

Abstract

Sertoli-Leydig cell tumor (SLCT) which belong to the group of sex-cord stromal tumors is a rare ovarian tumor. It usually develops the symptom of masculinization by excessive testosterone from the Leydig cell. In most cases, SLCTs are unilaterally localized (97-98%) and prognosis prove generally favorable with 5-year survival rate (79-90%). Recurrence is rare after a complete resection as well. Rare SLCTs secrete the alpha-fetoprotein (AFP). There is a increasing tendency for the SLCTs that have heterologous elements and low differentiation to secrete the AFP, which is useful in diagnosis of recurrence. The association of a thyroid adenoma and a SLCT has been described rarely. The relation between these two tumors has been suggested on the basis of a relatively high incidence of thyroid adenomas in the presence of such an uncommon ovarian neoplasm. It seems likely that this tumor complex is genetically determined by the aspect of familial neoplastic syndromes. We experienced a case of Sertoli-Leydig cell tumor with AFP-producing Sertoli cells in a 33-years old woman who has past history of thyroid adenoma, amenorrhea and a huge abdominal mass. Therefore, we present it with a brief review of literature.

Key Words: Sertoli-Leydig cell tumor, Alpha-fetoprotein, Thyroid adenoma